問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

175Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

496Cases

2009-05-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-05-01 - 2014-05-31

Phase II

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

  • Condition/Disease

    SYSTEMIC LUPUS ERYTHEMATOSUS

  • Test Drug

    PF-04236921 Powder for Injection, 106 mg/vial

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2012-05-12 - 2015-05-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-02-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2011-08-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-06-30 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-08-02 - 2013-06-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

1 37 38 39 40 41 50
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB